TYBR Health Announces $30 Million Series A Financing to Expand Access to the B3 GEL® System

TYBR Health has successfully raised $30 million in Series A financing, a move aimed at enhancing the commercial access of its innovative B3 GEL® System, which is designed to protect healing tissues during orthopedic surgery. The funding round, announced on July 21, 2026, was led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners and existing investors. The capital will be utilized to broaden product indications and conduct clinical studies to evaluate the efficacy of the B3 GEL® System in tissue protection.

Founded in Houston, Texas, TYBR Health is dedicated to developing medical technology that improves healing and recovery following surgical procedures. The B3 GEL® System is an FDA-cleared, flowable extracellular matrix hydrogel that protects tendons, ligaments, muscles, and surrounding soft tissues post-surgery. Unlike traditional sheet-based barriers, the B3 GEL® conforms to complex anatomical structures and can be rapidly applied without complicating existing surgical workflows. This innovative approach addresses a significant gap in postoperative care, focusing on the biological conditions necessary for optimal healing.

The strategic rationale behind this funding is rooted in the evolving landscape of orthopedic surgery, where there is an increasing recognition of the importance of managing the healing environment in conjunction with mechanical repairs. Surgeons have historically focused on the structural aspects of repairs, but advancements in medical technology are shifting attention to the biological factors that influence recovery. TYBR Health’s B3 GEL® System is positioned to capitalize on this trend by providing surgeons with a straightforward solution that integrates seamlessly into their practices.

The participation of notable investors such as Vensana Capital and Mutual Capital Partners underscores the commercial potential of TYBR Health's offerings. Vensana Capital, with approximately $1 billion in capital under management, specializes in breakthrough innovations in medical technology. Mutual Capital Partners, focused on mission-driven teams, brings a wealth of experience in the medical device sector. Their involvement is expected to bolster TYBR Health’s growth trajectory and enhance its clinical evidence base, ultimately expanding its market reach.

The broader implications of this fundraising round reflect a growing interest in medical technologies that improve patient outcomes in surgical settings. As the healthcare industry increasingly emphasizes the importance of postoperative care, products like the B3 GEL® System are likely to gain traction among surgeons seeking to enhance recovery protocols. This shift not only presents opportunities for TYBR Health but also signals a potential transformation in how surgical procedures are approached, with a more holistic view of patient recovery taking center stage.